Truvestments Capital LLC Purchases Shares of 397 Danaher Co. (NYSE:DHR)

Truvestments Capital LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 397 shares of the conglomerate’s stock, valued at approximately $110,000.

Other institutional investors have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in Danaher during the second quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the second quarter worth about $25,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the third quarter worth about $40,000. Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter worth about $55,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Danaher during the second quarter worth about $51,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of DHR opened at $236.53 on Wednesday. The company has a market capitalization of $170.84 billion, a P/E ratio of 45.14, a price-to-earnings-growth ratio of 4.34 and a beta of 0.85. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $256.66 and a 200 day moving average of $259.81. Danaher Co. has a twelve month low of $215.68 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 earnings per share. As a group, equities research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DHR. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. KeyCorp increased their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a report on Thursday, October 31st. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird lowered their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.